Foundation Medicine Raises $33.5M to Support Commercialization of Cancer Dx Panel
October 19, 2011
Foundation Medicine Raises $33.5M to Support Commercialization of Cancer Dx Panel
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Foundation Medicine, MSKCC to Develop Sequencing-based Blood Cancer Test from DNA, RNA
May 8, 2013 / Clinical Sequencing News - Foundation Medicine Shows Sequencing-based Cancer Test Can ID Clinically Actionable Mutations
June 8, 2011 / Clinical Sequencing News - At AACR, Early Providers of NGS-based Cancer Panels Debate 'Actionable' Mutations, Regulatory Issues
April 10, 2013 / Clinical Sequencing News - Foundation Medicine, Novartis Ink New Deal for Clinical Oncology Programs
June 7, 2012 / GenomeWeb Daily News - Foundation Medicine Preps for June Launch of Cancer Dx; Looks to Expand to RNA-Seq
February 22, 2012 / Clinical Sequencing News